Trial reportLeukemia2022
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Abstract readClinical Trial, Phase IILetter
In one paragraph
Trial report in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 5 pooled it
14.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 5 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.British journal of haematology · 2026Pooled it
- American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.Arthritis & rheumatology (Hoboken, N.J.) · 2026Guideline
- Vacuolated Marrow Cytopenias from Copper Deficiency toInternational journal of molecular sciences · 2025Pooled it
- Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis.Annals of hematology · 2025Pooled it
- Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis.Bone marrow transplantation · 2024Pooled it
- Lung-Predominant Hyperinflammatory Syndrome in Therapy-Related Myelodysplastic Syndrome Responsive to Interleukin-1 Blockade.Hematology reports · 2026Article
- Myelodysplasia in VEXAS syndrome.Blood advances · 2026Review
- Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.American journal of hematology · 2026Article
- Epigenetic regulation of B cell tolerance and dysfunction in autoimmune disease.Nature reviews. Immunology · 2026Review
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- High frequency of CD95British journal of haematology · 2026Article
- VEXAS Syndrome: Clinical Features, Hematologic Involvement, and Clinical Outcomes of Current and Emerging Therapies.Hematology reports · 2026Review
- VEXAS syndrome.Nature reviews. Disease primers · 2026Review
- Navigating through uncertainty-Experience from the UK national VEXAS MDT.British journal of haematology · 2026Article
- Establishing a consensus definition of VEXAS flare for clinical research.Rheumatology (Oxford, England) · 2026Article
- Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies.Annals of the rheumatic diseases · 2026Article
- Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report.Frontiers in immunology · 2026Article
- Case Report: Early-onset VEXAS syndrome with recurrent pulmonary inflammation and myelodysplasia: a diagnostic and therapeutic challenge.Frontiers in immunology · 2026Article
- The profile of clinical and laboratory features of Chinese VEXAS syndrome patients with hematological abnormalities: a single-center case series.Frontiers in immunology · 2026Article
- Clinical, laboratory and genetic characteristics of VEXAS syndrome: a study on behalf of GESMD.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 20 institutions in 1 country.
Arsene Mekinian *Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, F-75012, Paris, France. arsene.mekinian@aphp.fr.ORCID http://orcid.org/0000-0003-2849-3049
Lin Pierre Zhao *Service d'hématologie, Université de Paris Cité, AP-HP, Hôpital Saint Louis, F-75010, Paris, France.ORCID http://orcid.org/0000-0001-5035-4470
Sylvie ChevretAPHP, Department of Biostatistics and Medical Information, APHP, Saint-Louis Hospital, Paris, INSERM, UMR-1153, ECSTRA Team, Paris, France.
Kristell DesseauxAPHP, Department of Biostatistics and Medical Information, APHP, Saint-Louis Hospital, Paris, INSERM, UMR-1153, ECSTRA Team, Paris, France.
Laurent PascalService d'hématologie, Hôpital Saint Vincent de Paul, Lille, France.
Thibaut ComontService d'hématologie, CHU Toulouse, Toulouse, France.
Alexandre MariaService de médecine interne CHU Montpellier, Montpellier, France.
Pierre PeterlinService d'hématologie, CHU Nantes, Nantes, France.
Louis TerriouService d'hématologie, CHU Lille, Lille, France.
Maud D'Aveni PineyService d'hématologie, CHU Nancy, Nancy, France.
Marie-Pierre GourinService d'hématologie, CHU Limoges, Limoges, France.ORCID http://orcid.org/0000-0002-0143-5327
Norbert VeyService d'hématologie, CHU Marseille, Marseille, France.ORCID http://orcid.org/0000-0001-7027-040X
Odile Beyne RauzyService d'hématologie, CHU Toulouse, Toulouse, France.
Vincent GrobostInternal Medicine Department, Clermont-Ferrand University Hospital, 1 Rue Lucie et Raymond Aubrac, 63003, Clermont Ferrand, France.
Holy BezanaharyService de médecine interne CHU Dupuytren 2, 87000, Limoges, France.
Sophie Dimicoli-SalazarService d'hématologie, CHU Bordeaux, Bordeaux, France.
Anne BanosService d'hématologie, Centre Hospitalier de Biarritz, Biarritz, France.
Stefan WickenhauserService d'hématologie, CHU Nimes, Nimes, France.
Benoit De RenzisService d'hématologie, CHU Clermont Ferrand, Clermont Ferrand, France.
Eric DurotService d'hématologie, CHU Reims, Reims, France.ORCID http://orcid.org/0000-0003-3463-0089
Shanti Natarajan-AméService d'hématologie, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Laurent VoillatService d'hématologie, CHU Limoges, Limoges, France.
Fatiha ChermatService d'hématologie, Université de Paris Cité, AP-HP, Hôpital Saint Louis, F-75010, Paris, France.
Karine LemaireService d'hématologie, Université de Paris Cité, AP-HP, Hôpital Saint Louis, F-75010, Paris, France.
Vincent JachietService de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, F-75012, Paris, France.
Chantal HimberlinService d'hématologie, CHU Reims, Reims, France.
Sylvain ThépotService d'hématologie, CHU d'Angers, Angers, France.
Jose Miguel Torregrosa DiazService d'hématologie, CHU de Poitiers, Poitiers, France.
Laurent FrenzelAP-HP, Hôpital Necker, Paris, France.
Emmanuel GyanService d'hématologie, CHRU de Tours - Bretonneau, Tours, France.ORCID http://orcid.org/0000-0002-7651-9189
Guillaume DenisService d'hématologie, CH de Rochefort, Rochefort, France.ORCID http://orcid.org/0000-0003-0434-265X
Pierre HirschService d'hématologie biologique, Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), AP-HP, Hôpital Saint Antoine, Paris, France.
Olivier KosmiderService d'hématologie biologique, APHP, Hôpital Cochin, Paris, France.ORCID http://orcid.org/0000-0002-6021-4057
Lionel AdesService d'hématologie, Université de Paris Cité, AP-HP, Hôpital Saint Louis, F-75010, Paris, France.ORCID http://orcid.org/0000-0002-9020-8766
Olivier FainService de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, F-75012, Paris, France.
Pierre FenauxService d'hématologie, Université de Paris Cité, AP-HP, Hôpital Saint Louis, F-75010, Paris, France.
Université Paris Cité · FRInserm · FRSorbonne Université · FRCentre Hospitalier Universitaire de Limoges · FRCentre Hospitalier Universitaire de Reims · FRCentre Hospitalier Universitaire de Toulouse · FRCentre Hospitalier de Bigorre · FRCentre Hospitalier de Rochefort · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Lille · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Nîmes · FRCentre Hospitalier Universitaire de Poitiers · FRCentre Hospitalier Universitaire de Tours · FRDélégation Provence et Corse · FRHôpital Cochin · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesAzacitidineHumansProspective StudiesSteroidsAzacitidineSteroids
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.